Donghu Zhou

Donghu Zhou

Auto-generated profile, based on publicly available information

Donghu Zhou

Laboratory of Molecular Biology, Beijing Institute of Clinical Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2018 in Liver International
Verified
Journal Article
Closed access
PDF file
WZWei Zhang
Wei Zhang
AXAnjian Xu
Anjian Xu
YLYanmeng Li
Yanmeng Li
SZSuxian Zhao
Suxian Zhao
DZDonghu Zhou
Donghu Zhou
OGon behalf of China Registry of Genetic/Metabolic Liver Diseases (CR‐GMLD) Group
on behalf of China Registry of Genetic/Metabolic Liver Diseases (CR‐GMLD) Group

31 January 2019 in Human Mutation
Verified
Journal Article
Closed access
PDF file
XLXiaojin Li
Xiaojin Li
WZWei Zhang
Wei Zhang
DZDonghu Zhou
Donghu Zhou
TLTingxia Lv
Tingxia Lv
AXAnjian Xu
Anjian Xu
JHJian Huang
Jian Huang

9 October 2024 in Cellular and Molecular Gastroenterology and Hepatology
Verified
Journal Article
Open access
DZDonghu Zhou
Donghu Zhou
HZHuaduan Zi
Huaduan Zi
XYXiaoxi Yang
Xiaoxi Yang
XLXiaojin Li
Xiaojin Li
YLYanmeng Li
Yanmeng Li
HYHong You
Hong You
The association between Wilson disease and various ATP7B mutations is well-established; however, the molecular mechanism underlying the functional consequence of these mutations, particularly the splicing mutations, remains unclear. This study focused on the ATP7B c.1543+1G>C variant, to reveal a universal pathogenic mechanism of the ATP7B mutants with altered N-terminus. The splicing assay and RNA pull-down were performed to explore the mechanism of the aberrant splicing. The ATP7B knockout HuH-7 cell line and Atp7b-/- mice were created, and the functional consequence of the mutant ATP7B were evaluated in vitro and in vivo. The c.1543+1G>C mutation resulted in the skipping of ATP7B exon 3, and the mutant ATP7B showed a loss of trans-Golgi network localization and was degraded via the ubiquitin-proteasome pathway, facilitated by enhanced interactions with COMMD1. Elevated intercellular copper concentration and reduced survival rate were observed in HuH-7 cells expressing mutant ATP7B. Restoration of wild-type ATP7B in Atp7b-/- mice resulted in a substantial improvement in phenotype, whereas mice treated with mutant ATP7B did not demonstrate equivalent benefits. Our research investigated the pathogenicity and mechanism of ATP7B c.1543+1G>C variant, with particular focus on its enhanced interaction with COMMD1 as a potential universal mechanism contributing to the dysfunction of various ATP7B variants. These findings provide a foundation for the development of innovative therapeutic strategies that target abnormal splicing events in a range of hereditary diseases, including Wilson disease.

31 March 2022 in Metallomics
Verified
Journal Article
Open access
PDF file
DZDonghu Zhou
Donghu Zhou
SJSiyu Jia
Siyu Jia
LYLiping Yi
Liping Yi
ZWZhen Wu
Zhen Wu
YSYi Song
Yi Song
HYHong You
Hong You
The mutations in modifier genes may contribute to some inherited diseases including Wilson disease (WD). This study was designed to identify potential modifier genes that contribute to WD. A total of 10 WD patients with single or no heterozygous ATP7B mutations were recruited for whole-exome sequencing (WES). Five hundred and thirteen candidate genes, of which the genetic variants present in at least two patients, were identified. In order to clarify which proteins might be involved in copper transfer or metabolism processes, the isobaric tags for relative and absolute quantitation (iTRAQ) was performed to identify the differentially expressed proteins between normal and CuSO4-treated cell lines. Thirteen genes/proteins were identified by both WES and iTRAQ, indicating that disease-causing variants of these genes may actually contribute to the aberrant copper ion accumulation. Additionally, the c.86C > T (p.S29L) mutation in the SLC31A2 gene (coding CTR2) has a relative higher frequency in our cohort of WD patients (6/191) than reported (0.0024 in gnomAD database) in our healthy donors (0/109), and CTR2S29L leads to increased intracellular Cu concentration and Cu-induced apoptosis in cultured cell lines. In conclusion, the WES and iTRAQ approaches successfully identified several disease-causing variants in potential modifier genes that may be involved in the WD phenotype.

7 July 2025 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
QOQin Ouyang
Qin Ouyang
SJSiyu Jia
Siyu Jia
QZQianyu Zhu
Qianyu Zhu
YLYanmeng Li
Yanmeng Li
HZHuaduan Zi
Huaduan Zi
JHJian Huang
Jian Huang
Despite advancements in diagnostic and therapeutic strategies, hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality. Antioxidant-1 (ATOX1) has been implicated in oncogenic processes across various cancer types; however, its specific role in HCC remains unclear. This study aimed to investigate the function of ATOX1 and its underlying molecular mechanisms in HCC.

13 February 2025 in Carcinogenesis
Verified
Journal Article
Closed access
HTHengcheng Tang
Hengcheng Tang
HZHuaduan Zi
Huaduan Zi
DZDonghu Zhou
Donghu Zhou
YLYanmeng Li
Yanmeng Li
XLXiaojin Li
Xiaojin Li
JHJian Huang
Jian Huang
Resistance to platinum-based chemotherapy agents like oxaliplatin (OXA) poses significant challenges in the treatment of cancers such as hepatocellular carcinoma (HCC). Centrin 2 (CETN2), which functions in nucleotide excision repair (NER) of DNA damage, is overexpressed in HCC. We investigated the potential role of CETN2 in modulating the sensitivity of HCC cells to OXA. CETN2 expression correlated with decreased OXA sensitivity in Huh7 and Hep3B HCC cell lines. CETN2 forms a complex with XPC, which is crucial for the initial DNA damage recognition in NER, thereby enhancing NER and reducing the efficacy of OXA. siRNA-mediated knockdown of CETN2 increased OXA-induced cytotoxicity and apoptosis, confirming its role in chemoresistance. Moreover, overexpression of CETN2 inhibited OXA-induced DNA damage, an effect partially reversed by XPC knockdown. Our findings highlight CETN2 as a potential biomarker and therapeutic target in overcoming OXA resistance in HCC and suggest the possibility for CETN2 inhibitors in enhancing chemotherapeutic efficacy in the treatment of HCC.